December 1, 2022
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced its conference schedule for December 2022.
November 10, 2022
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced its conference schedule for November 2022.
November 3, 2022
Company’s launch of Biodata Network offers new portfolio of data-driven solutions Collaboration with BC Platforms increases access to data-driven genomic insights via Global Data Partner Network, BCRQUEST.com Tranche of 80,000 genetic sequences made accessible online for research and drug discovery
July 15, 2022
On Track for FY 2022 Guidance Q1 2022 revenue rises 3% to €10.3 million Completed phase out of COVID-19 Business segment in Q1 2022 Positioning Pharma and Diagnostics for post-COVID recovery and growth in 2022 and beyond Reaffirms FY 2022 guidance of 15-20% revenue growth CAMBRIDGE, Mass.
Displaying 1 - 10 of 26